Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 of its ELEVATE-45-201 Phase 1/2 study at an increased dose of 10 mg/kg (up from 5 mg/kg in Cohort 1). The study evaluates ENTR-601-45 for treating Duchenne muscular dystrophy in exon 45 skipping amenable patients. The company remains on track to report Cohort 1 safety and pharmacokinetic data in mid-2026.

06/02/2026, 7:00 AM • GlobeNewswire

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

05/26/2026, 1:00 PM • GlobeNewswire

INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

Law firm Holzer & Holzer is investigating whether Entrada Therapeutics complied with federal securities laws following disappointing topline results from its ELEVATE-44-201 Duchenne muscular dystrophy study. Cohort 1 showed a 2.36% increase in dystrophin, falling below analyst expectations and causing the stock price to decline. The firm is seeking investors who suffered losses.

05/18/2026, 8:00 AM • GlobeNewswire

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Entrada Therapeutics (NASDAQ: TRDA) for allegedly issuing false or misleading statements regarding Phase 1/2 clinical trial results. The company characterized topline data from the ELEVATE-44-201 study as 'positive,' but results showed only marginal protein production improvements, falling short of competitive market standards. The stock plummeted 57.3% following the May 7, 2026 announcement.

05/17/2026, 9:54 PM • GlobeNewswire

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by end of 2026, and submit regulatory applications for ENTR-601-51 in 2026. Entrada selected ENTR-801 as its first clinical candidate for Usher syndrome type 2A treatment and plans to nominate a second ocular candidate in 2026. The company maintains cash runway into Q3 2027.

01/08/2026, 7:00 AM • GlobeNewswire

Questex’s Fierce Life Sciences Announces 2025 Innovation Awards Winners

Questex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.

11/19/2025, 12:00 PM • GlobeNewswire

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

5AM Venture Management sold its entire 189,593 share stake in Viking Therapeutics, representing a $5.02 million position change. The sale appears to be a portfolio rebalancing rather than a lack of confidence in the company's potential.

11/18/2025, 2:11 PM • The Motley Fool

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics awarded $50,000 grants to Jett Foundation and Parent Project aps to support Duchenne muscular dystrophy community initiatives focused on equity, accessibility, and inclusion in the U.S. and Italy.

09/05/2025, 7:00 AM • GlobeNewswire

Entrada (TRDA) Q2 Revenue Drops 98%

Entrada Therapeutics reported a significant revenue drop and wider-than-expected loss in Q2 2025, primarily due to the conclusion of its partnership with Vertex Pharmaceuticals. Despite financial challenges, the company continues advancing its clinical pipeline for neuromuscular and genetic disease therapies.

08/06/2025, 7:21 PM • The Motley Fool